| Literature DB >> 34773051 |
Raees Tonse1, Alexandra Townsend2, Muni Rubens3, Vitaly Siomin2,4, Michael W McDermott2,4, Martin C Tom1,2, Matthew D Hall1,2, Yazmin Odia2,5, Manmeet S Ahluwalia2,6, Minesh P Mehta1,2, Rupesh Kotecha7,8.
Abstract
The purpose of this study was to critically analyze the risk of unplanned readmission following resection of brain metastasis and to identify key risk factors to allow for early intervention strategies in high-risk patients. We analyzed data from the Nationwide Readmissions Database (NRD) from 2010-2014, and included patients who underwent craniotomy for brain metastasis, identified using ICD-9-CM diagnosis (198.3) and procedure (01.59) codes. The primary outcome of the study was unplanned 30-day all-cause readmission rate. Secondary outcomes included reasons and costs of readmissions. Hierarchical logistic regression model was used to identify the factors associated with 30-day readmission following craniotomy for brain metastasis. During the study period, 44,846 index hospitalizations occurred for patients who underwent resection of brain metastasis. In this cohort, 17.8% (n = 7,965) had unplanned readmissions within the first 30 days after discharge from the index hospitalization. The readmission rate did not change significantly during the five-year study period (p-trend = 0.286). The median per-patient cost for 30-day unplanned readmission was $11,109 and this amounted to a total of $26.4 million per year, which extrapolates to a national expenditure of $269.6 million. Increasing age, male sex, insurance status, Elixhauser comorbidity index, length of stay, teaching status of the hospital, neurological complications and infectious complications were associated with 30-day readmission following discharge after an index admission for craniotomy for brain metastasis. Unplanned readmission rates after resection of brain metastasis remain high and involve substantial healthcare expenditures. Developing tools and interventions to prevent avoidable readmissions could focus on the high-risk patients as a future strategy to decrease substantial healthcare expense.Entities:
Mesh:
Year: 2021 PMID: 34773051 PMCID: PMC8589950 DOI: 10.1038/s41598-021-01641-4
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1CONSORT diagram for inclusion criteria of the study.
Demographic, hospital, and clinical characteristics during principal admissions of patients undergoing resection for brain metastasis in the United States, 2010–2014.
| Variables | Index cases | Unplanned 30-day readmission | ||
|---|---|---|---|---|
| Yes | No | |||
| Total sample (unweighted) | 18,888 | 3,304 | 15,584 | |
| Total sample (weighted) | 44,846 | 7,965 | 36,849 | |
| 0.338 | ||||
| 0–17 years | 0.90% (0.12) | 1.2% (0.23) | 0.80% (0.13) | |
| 18–39 years | 4.6% (0.19) | 4.9% (0.46) | 4.6% (0.19) | |
| 40–64 years | 56.4% (0.50) | 55.1% (1.1) | 56.6% (0.52) | |
| ≥ 65 years | 38.1% (0.53) | 38.8% (1.1) | 38.0% (0.53) | |
| Female, % (SE) | 51.8% (0.45) | 46.4% (1.1) | 53.0% (0.47) | < 0.001 |
| < 0.001 | ||||
| Medicare | 40.7% (0.53) | 42.5% (1.1) | 40.4% (0.54) | |
| Medicaid | 13.3% (0.39) | 14.8% (0.79) | 12.9% (0.42) | |
| Private | 39.7% (0.62) | 37.2% (1.2) | 40.1% (0.63) | |
| Self-pay | 2.5% (0.15) | 1.9% (0.27) | 2.6% (0.17) | |
| No charge | 0.20% (0.04) | 0.20% (0.08) | 0.20% (0.04) | |
| Other | 3.7% (0.24) | 3.4% (0.41) | 3.8% (0.24) | |
| 0.290 | ||||
| Quartile 1 | 25.8% (0.76) | 27.4% (1.2) | 25.4% (0.76) | |
| Quartile 2 | 25.0% (0.58) | 24.5% (1.0) | 25.1% (0.61) | |
| Quartile 3 | 25.0% (0.5) | 24.7% (0.91) | 25.1% (0.53) | |
| Quartile 4 | 24.1% (0.85) | 23.3% (1.0) | 24.4% (0.88) | |
| 0.003 | ||||
| Small | 6.1% (0.91) | 7.9% (0.75) | 6.1% (0.89) | |
| Medium | 16.3% (0.88) | 17.3% (1.1) | 16.5% (0.88) | |
| Large | 77.6% (1.2) | 74.7% (1.3) | 77.4% (1.2) | |
| < 0.001 | ||||
| Metropolitan non-teaching | 19.4% (0.73) | 24.0% (0.98) | 19.5% (0.76) | |
| Metropolitan teaching | 79.1% (0.77) | 71.3% (1.1) | 78.9% (0.79) | |
| Non-metropolitan hospital | 1.5% (0.20) | 4.6% (0.36) | 1.6% (0.20) | |
| 0.026 | ||||
| Government, nonfederal | 15.3% (1.4) | 13.9% (1.2) | 15.2% (1.3) | |
| Private, not-profit | 75.9% (1.5) | 75.9% (1.6) | 76.0% (1.5) | |
| Private, invest-own | 8.8% (0.86) | 10.3% (1.2) | 8.8% (0.84) | |
| Elixhauser comorbidity index > 3, % (SE) | 26.4% (0.49) | 37.9% (1.2) | 25% (0.49) | < 0.001 |
| Length of stay ≥ 5 days, % (SE) | 57.3% (0.70) | 52% (1.0) | 56.1% (0.72) | < 0.001 |
| Death, % (SE) | – | 8.7% (0.54) | – | – |
Complications during principal admission of patients undergoing resection for brain metastasis in the United States, 2010–2014.
| Complications | Unplanned 30-day readmission | ||
|---|---|---|---|
| Yes | No | ||
| Mechanical wound, % (SE) | 1.2% (0.19) | 0.48% (0.07) | < 0.001 |
| Neurological complications, % (SE) | 10.2% (0.33) | 8.8% (0.57) | 0.035 |
| Infection complications, % (SE) | 7.1% (0.5) | 0.39% (0.06) | < 0.001 |
| Urinary complications, % (SE) | 0.20% (0.15) | 0.25% (0.07) | 0.753 |
| Pulmonary complications, % (SE) | 1.3% (0.12) | 0.61% (0.13) | < 0.001 |
| Gastrointestinal complications, % (SE) | 0.11% (0.05) | 0.03% (0.01) | 0.031 |
| Cardiovascular complications, % (SE) | 2.6% (0.4) | 1.9% (0.14) | 0.037 |
| Systemic complications, % (SE) | 0.41% (0.09) | 0.18% (0.05) | 0.015 |
| Complications during the surgical procedure, % (SE) | 0.28% (0.09) | 0.49% (0.06) | 0.086 |
Figure 2Primary reasons for readmissions by percent volume and median hospitalization charge following resection for brain metastasis.
Regression analysis showing factors associated with readmission following craniotomy for brain metastasis in the United States, 2010–2014.
| Year | Odds ratio (95% CI) |
|---|---|
| 2010 | Reference |
| 2011 | 0.984 (0.852–1.136) |
| 2012 | 1.028 (0.885–1.194) |
| 2013 | 0.929 (0.803–1.074) |
| 2014 | 0.983 (0.853–1.133) |
| 0–17 years | Reference |
| 18–39 years | 0.82 (0.471–1.429) |
| 40–64 years | 1.555 (1.348–1.672) |
| ≥ 65 years | 1.786 (1.401–1.974) |
| Male | 1.29 (1.172–1.419) |
| Medicare | Reference |
| Medicaid | 1.513 (1.338–1.625) |
| No charge | 0.713 (0.272–1.87) |
| Other pay | 0.765 (0.565–1.035) |
| Private | 0.918 (0.783–1.077) |
| Self-pay | 0.587 (0.413–0.833) |
| Quartile 1 | Reference |
| Quartile 2 | 0.947 (0.818–1.096) |
| Quartile 3 | 0.957 (0.832–1.100) |
| Quartile 4 | 0.929 (0.812–1.064) |
| Elixhauser comorbidity index > 3 | 1.374 (1.239–1.523) |
| Length of stay ≥ 5 days | 1.215 (1.1–1.343) |
| Small | Reference |
| Large | 0.934 (0.796–1.095) |
| Medium | 0.831 (0.685–1.009) |
| Metropolitan non-teaching | Reference |
| Metropolitan teaching | 1.291 (1.163–1.436) |
| Non-metropolitan hospital | 0.872 (0.602–0.962) |
| Government, nonfederal | Reference |
| Private, invest-own | 1.042 (0.831–1.308) |
| Private, not-profit | 0.984 (0.86–1.125) |
| Mechanical complications | 0.781 (0.392–1.555) |
| Neurological complications | 1.178 (1.027–1.35) |
| Infectious complications | 1.447 (1.233–2.859) |
| Urinary complications | 1.054 (0.447–2.488) |
| Respiratory complications | 0.923 (0.664–1.283) |
| Cardiovascular complications | 0.805 (0.586–1.106) |
| Systemic complications | 0.908 (0.353–2.338) |
| Surgical complications | 0.867 (0.492–1.528) |